Login to Your Account

'Serious' Concerns Could Derail Elesclomol

Synta, Amicus Take Tumbles as Safety Issues Halt Studies

By Jennifer Boggs

Monday, March 2, 2009
Emerging patient safety concerns sent shares of Synta Pharmaceuticals Corp. and Amicus Therapeutics Inc. plunging Friday, as Synta halted development of its late-stage melanoma drug elesclomol due to a higher-than-expected death rate and Amicus suspended a Phase II trial of Pompe disease drug AT2220 after two patients suffered adverse events. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription